Antiangiogenic agents and endothelin antagonists in advanced castration resistant prostate cancer

European Journal of Cancer

Volumn 47, Issue 12, 2011, Pages 1846-1851

  Merino, M ^a   Pinto, A ^a   Gonzalez R ^a   Espinosa, E ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Angiogenesis; Bevacizumab; Endothelin antagonists; Prostate cancer; Tyrosine kinase inhibitors

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; ATRASENTAN; BEVACIZUMAB; CEDIRANIB; DOCETAXEL; ENDOTHELIN RECEPTOR ANTAGONIST; ENZASTAURIN; ESTRAMUSTINE; GONADOTROPIN DERIVATIVE; IMMUNOMODULATING AGENT; LENALIDOMIDE; PACLITAXEL; PAZOPANIB; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; THALIDOMIDE; VANDETANIB; VASCULOTROPIN INHIBITOR; ZIBOTENTAN;

ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; ASTHENIA; BLEEDING; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CONSTIPATION; DIARRHEA; DISEASE FREE SURVIVAL; DIZZINESS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; EDEMA; FEBRILE NEUTROPENIA; FOLLOW UP; HEADACHE; HUMAN; HYPERTENSION; MONOTHERAPY; NAUSEA; NEPHRITIS; NEUTROPENIA; NOSE CONGESTION; OVERALL SURVIVAL; PERFORATION; PERIPHERAL EDEMA; PRIORITY JOURNAL; RASH; REVIEW; RHINITIS; THROMBOEMBOLISM; THROMBOSIS; UNSPECIFIED SIDE EFFECT; VOMITING; XEROSTOMIA;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS, HORMONAL; BENZENESULFONATES; CASTRATION; DRUG RESISTANCE, NEOPLASM; ENDOTHELINS; HUMANS; INDOLES; MALE; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIDINES; PYRROLES; PYRROLIDINES; QUINAZOLINES; RECEPTORS, ENDOTHELIN; THALIDOMIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80051552737     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.04.020     Document Type: Article

References (36)

1. C. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics, 2010 CA Cancer J Clin 60 5 2010 277 300
2. D.R. Berthold, G.R. Pond, and F. Soban Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX327 study J Clin Oncol 26 2 2008 242 245
3. J.S. De Bono, S. Oudard, and M. Ozquroglu Prednisone plus cabacitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open label trial Lancet 376 9747 2010 1147 1154
4. S.K. Pal, and O. Sartor Phase III data for abiraterone in an involving landscape for castration-resistant prostate cancer Maturitas 68 2 2011 103 105
5. N. Weidner, P.R. Carroll, J. Flax, W. Blumenfeld, and J. Folkman Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma Am J Pathol 143 2 1993 401 409 (Pubitemid 24058195)
6. J.L. Duque, K.R. Loughlin, and R.M. Adam Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer Urology 54 3 1999 523 527 (Pubitemid 29407032)
7. D.M. Reese, P. Fratesi, M. Corry, and W. Novotny A phase II trial of humanized anti-vascular endothelial growth factor antibody for the treatment of androgen-independent prostate cancer Prostate J 3 2 2001 65 70 (Pubitemid 34169203)
8. G. Di Lorenzo, W.D. Figg, and S.D. Fossa Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study Eur Urol 54 5 2008 1089 1094
9. M.D. Picus, S. Halabi, and W.K. Kelly A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer Cancer 117 3 2011 526 533
10. W.K. Kelly, S. Halabi, and M.A. Carducci A randomized, double-blind, placebo-controlled phase III trial comparing docetael, prednisone, and pacebo with docetaxel, prednisone, and bevacizumab inmen with metastatic castration-resistant prostate cancer: survival results of CALGB 90401 J Clin Oncol 28 2010 18s [suppl.; abstr. LBA4511]
11. B.I. Rini, V. Weinberg, and L. Fong Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (Provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy Cancer 107 1 2006 67 74 (Pubitemid 43939032)
12. S. Steinbild, K. Mross, and A. Frost A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIVA Br J Cancer 97 11 2007 1480 1485 (Pubitemid 350175850)
13. W.L. Dahut, C. Scripture, and E. Posadas A phase II trial of sorafenib in androgen-independent prostate cancer Clin Cancer Res 14 1 2008 209 214 (Pubitemid 351377997)
14. J.B. Aragon-Ching, L. Jain, and J.L. Gulley Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer BJU 103 12 2009 1636 1640
15. H.J. Scher, S. Halabi, and I. Tannok Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group J Clin Oncol 26 7 2008 1148 1159
16. A.J. Zurita, G. Liu, and T. Hutson Sunitinib in combination with docetaxel and prednisone in patients with metastatic hormone-refractory prostate cancer J Clin Oncol 27 2009 15s [suppl.; abstr. 5166]
17. D.M. Michaelson, M.M. Regan, and W.K. Oh Phase II study of sunitinib in advanced prostate cancer Ann Oncol 20 5 2009 913 920
18. G. Sonpavde, P.O. Periman, and D. Bernold Sunitinib malate for castration-resistant prostate cancer following docetaxel-based chemotherapy Ann Oncol 21 2 2010 319 324
19. Adelberg D, Karakunnel JJ, Gulley JL, et al. A phase II study of cediranib in post-docetaxel in castration resistant prostate cancer. 2010 ASCO Genitourinary Cancer Symposium, abstr. 63; 2010.
20. M.A. Carducci, D.K. Armstrong, and C. Collins Phase I of enzastaurin and bevacizumab in patients with advanced cancer: safety, pharmacokinetics and response assessment J Clin Oncol 27 2009 15s [suppl.; abstr. 3517]
21. W. Stadler, D. Cao, and N.J. Vogelzang A randomized phase II trial of the antiangiogenic agent SU5416 in hormone refractory prostate cancer Clin Cancer Res 10 10 2004 3365 3370 (Pubitemid 38685441)
22. W.D. Figg, W. Dahut, and P.A. Duray A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer Clin Cancer Res 7 7 2001 1888 1893 (Pubitemid 32994822)
23. M.J. Drake, W. Robson, and P. Mehta An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer Br J Cancer 88 6 2003 822 827 (Pubitemid 36520866)
24. W.L. Dahut, J.L. Gulley, and P.M. Arlen Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer J Clin Oncol 22 13 2004 2532 2539 (Pubitemid 41103740)
25. W.D. Figg, M.H. Hussain, and J.L. Gulley A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation J Urol 181 3 2009 1104 1113
26. Y.M. Ning, J.L. Gulley, and P.M. Arlen Phase II trial of bevacizumab, thalidomide, docetaxel and prednisone in patients with metastatic castration resistant prostate cancer J Clin Oncol 28 12 2010 2070 2076
27. Moss RA, Mohile SG, Shelton G, Melia J, Petrylak DP. A phase I open-label study using lenalidomide and docetaxel in androgen-independent prostate cancer. ASCO Prostate Cancer Symposium 2007, abstr. 89; 2007.
28. L. Pagliaro, N. Tannir, and S. Tu A modular phase I study of lenalidomide and paclitaxel in metastatic castrate resistant prostate cancer with prior taxane therapy J Clin Oncol 26 2008 [suppl.; abstr. 13545]
29. D. Keizman, V.J. Sinibaldi, and M.A. Carducci Phase I/II double-blinded randomized study to determine the tolerability an efficacy of two different doses of lenalidomide in biochemically relapsed prostate cancer patients J Clin Oncol 28 2010 15s [suppl.; abstr. 4554]
30. X. Huang, Y.M. Ning, and J.L. Gulley Phase II trial of bevacizumab, lenalidomide, docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer J Clin Oncol 29 2011 [suppl. 7; abstr. 138]
31. M.A. Carducci, R.J. Padley, and J. Breul Effect of endothelin - a receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II placebo-controlled trial J Clin Oncol 21 4 2003 679 689 (Pubitemid 46621903)
32. M.A. Carducci, F. Saad, and P.A. Abrahamsson A phase III randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer Cancer 110 9 2007 1959 1966 (Pubitemid 350036854)
33. Vogelzang NJ, Nelson JB, Schulman CC. Meta-analysis of clinical trials of atrasentan 10 mg in metastatic hormone-refractory prostate cancer. 2005 ASCO Annual Meeting Proceedings, vol. 23. No. 16S, Part I of II.
34. Moore CN, Creel P, Petros W, et al. Phase I/II study of docetaxel and atrasentan in men with metastatic hormone-refractory prostate cancer. J Clin Oncol. 2006 ASCO Annual Meeting Proceedings Part I, vol. 24, No. 18S (suppl.); 2006. p. 14504.
35. http://clinicaltrials.gov/ct2/show/NCT00134056.
36. N.D. James, A. Caty, and H. Payne Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan in patients with metastatic castration-resistant prostate cancer and bone metastases cho were pain-free or mydly symptomatic for pain: a double-blind, placebo controlled, randomized phase II trial BJU Int 106 7 2010 966 973